These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 21345633)

  • 1. Contrast-enhanced ultrasonic parametric perfusion imaging in the evaluation of antiangiogenic tumor treatment.
    Zhou JH; Zheng W; Cao LH; Liu M; Luo RZ; Han F; Wu PH; Li AH
    Eur J Radiol; 2012 Jun; 81(6):1360-5. PubMed ID: 21345633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contrast-enhanced gray-scale ultrasound for quantitative evaluation of tumor response to chemotherapy: preliminary results with a mouse hepatoma model.
    Zhou JH; Cao LH; Zheng W; Liu M; Han F; Li AH
    AJR Am J Roentgenol; 2011 Jan; 196(1):W13-7. PubMed ID: 21178025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative assessment of tumor blood flow in mice after treatment with different doses of an antiangiogenic agent with contrast-enhanced destruction-replenishment US.
    Zhou JH; Cao LH; Liu JB; Zheng W; Liu M; Luo RZ; Han F; Li AH
    Radiology; 2011 May; 259(2):406-13. PubMed ID: 21292869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative evaluation of viable tissue perfusion changes with contrast-enhanced greyscale ultrasound in a mouse hepatoma model following treatment with different doses of thalidomide.
    Zhou JH; Zheng W; Cao LH; Liu M; Luo RZ; Han F; Wu PH; Li AH
    Br J Radiol; 2011 Sep; 84(1005):826-32. PubMed ID: 21224299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative Evaluation of Combretastatin A4 Phosphate Early Efficacy in a Tumor Model with Dynamic Contrast-Enhanced Ultrasound.
    Zhang P; Chen Y; Liu J; Yang Y; Lv Q; Wang J; Zhang L; Xie M
    Ultrasound Med Biol; 2018 Apr; 44(4):840-852. PubMed ID: 29395676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic contrast-enhanced ultrasound parametric maps to evaluate intratumoral vascularization.
    Pitre-Champagnat S; Leguerney I; Bosq J; Peronneau P; Kiessling F; Calmels L; Coulot J; Lassau N
    Invest Radiol; 2015 Apr; 50(4):212-7. PubMed ID: 25275834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contrast-enhanced US quantitatively detects changes of tumor perfusion in a murine breast cancer model during adriamycin chemotherapy.
    Wang JW; Cao LH; Han F; Zheng W; Chen Y; Li AH; Zhou JH
    Acta Radiol; 2013 Oct; 54(8):882-8. PubMed ID: 23761553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results.
    Lassau N; Koscielny S; Chami L; Chebil M; Benatsou B; Roche A; Ducreux M; Malka D; Boige V
    Radiology; 2011 Jan; 258(1):291-300. PubMed ID: 20980447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stress Test of Contrast-Enhanced US with Phenylephrine in a Rabbit VX2 Liver Tumor Model: Differentiating Benign Periablational Enhancement from Residual Tumor after Radiofrequency Ablation.
    Kan X; Zhang Y; Zheng C; Li L; Chen J; Wu Y; Guo T; Xiong B
    J Vasc Interv Radiol; 2016 Jul; 27(7):1077-1085.e2. PubMed ID: 27117950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic tumor treatment: noninvasive monitoring with contrast pulse sequence imaging for contrast-enhanced grayscale ultrasound.
    Zhou J; Zheng W; Cao L; Liu M; Han F; Li A
    Acad Radiol; 2010 May; 17(5):646-51. PubMed ID: 20223684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrast-enhanced ultrasonography of hepatocellular carcinoma: correlation between quantitative parameters and arteries in neoangiogenesis or sinusoidal capillarization.
    Pei XQ; Liu LZ; Zheng W; Cai MY; Han F; He JH; Li AH; Chen MS
    Eur J Radiol; 2012 Mar; 81(3):e182-8. PubMed ID: 21349669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.
    Sugimoto K; Moriyasu F; Saito K; Rognin N; Kamiyama N; Furuichi Y; Imai Y
    Liver Int; 2013 Apr; 33(4):605-15. PubMed ID: 23305331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST).
    Jiang T; Kambadakone A; Kulkarni NM; Zhu AX; Sahani DV
    Invest Radiol; 2012 Jan; 47(1):11-7. PubMed ID: 21512396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood flow changes in hepatocellular carcinoma after the administration of thalidomide assessed by reperfusion kinetics during microbubble infusion: preliminary results.
    Bertolotto M; Pozzato G; Crocè LS; Nascimben F; Gasparini C; Cova MA; Tiribelli C
    Invest Radiol; 2006 Jan; 41(1):15-21. PubMed ID: 16355035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noninvasive contrast-enhanced US quantitative assessment of tumor microcirculation in a murine model: effect of discontinuing anti-VEGF therapy.
    Guibal A; Taillade L; Mulé S; Comperat E; Badachi Y; Golmard JL; Le Guillou-Buffello D; Rixe O; Bridal SL; Lucidarme O
    Radiology; 2010 Feb; 254(2):420-9. PubMed ID: 20093514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of portal vein tumor thrombosis in quantitative perfusion analysis of contrast-enhanced ultrasound of hepatocellular carcinoma.
    Wang Z; Liu G; Lu MD; Xie X; Kuang M; Wang W; Xu Z; Lin M; Chen L
    Ultrasound Med Biol; 2015 May; 41(5):1277-86. PubMed ID: 25623820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contrast ultrasonography: necessity of linear data processing for the quantification of tumor vascularization.
    Peronneau P; Lassau N; Leguerney I; Roche A; Cosgrove D
    Ultraschall Med; 2010 Aug; 31(4):370-8. PubMed ID: 20577941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound.
    Zocco MA; Garcovich M; Lupascu A; Di Stasio E; Roccarina D; Annicchiarico BE; Riccardi L; Ainora ME; Ponziani F; Caracciolo G; Rapaccini GL; Landolfi R; Siciliano M; Pompili M; Gasbarrini A
    J Hepatol; 2013 Nov; 59(5):1014-21. PubMed ID: 23811306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of tumor microvascular response to brivanib by dynamic contrast-enhanced 7-T MRI in an orthotopic xenograft model of hepatocellular carcinoma.
    Song KD; Choi D; Lee JH; Im GH; Yang J; Kim JH; Lee WJ
    AJR Am J Roentgenol; 2014 Jun; 202(6):W559-66. PubMed ID: 24848850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study.
    Wang J; Chen LT; Tsang YM; Liu TW; Shih TT
    AJR Am J Roentgenol; 2004 Sep; 183(3):713-9. PubMed ID: 15333360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.